Left atrial size predicts outcome in severe but asymptomatic mitral regurgitation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 03 2023
Historique:
received: 14 12 2021
accepted: 07 03 2023
entrez: 8 3 2023
pubmed: 9 3 2023
medline: 11 3 2023
Statut: epublish

Résumé

Patients with severe asymptomatic primary mitral regurgitation (MR) can be safely managed with an active surveillance strategy. Left atrial (LA) size is affected by MR severity, left ventricular function and is also associated with the risk of atrial fibrillation and may be an integrative parameter for risk stratification. The present study sought to determine the predictive value of LA size in a large series of asymptomatic patients with severe MR. 280 consecutive patients (88 female, median age 58 years) with severe primary MR and no guideline-based indications for surgery were included in a follow-up program until criteria for mitral surgery were reached. Event-free survival was determined and potential predictors of outcome were assessed. Survival free of any indication for surgery was 78% at 2 years, 52% at 6 years, 35% at 10 years and 19% at 15 years, respectively. Left atrial (LA) diameter was the strongest independent echocardiographic predictor of event-free survival with incremental predictive value for the thresholds of 50, 60 and 70 mm, respectively. In a multivariable analysis that encompassed age at baseline, previous history of atrial fibrillation, left ventricular end systolic diameter), LA diameter, sPAP > 50 mmHg and year of inclusion, LA diameter was the strongest independent echocardiographic predictor of event-free survival (adjusted HR = 1.039, p < 0.001). LA size is a simple and reproducible predictor of outcome in asymptomatic severe primary MR. In particular, it may help to identify patients who may benefit from early elective valve surgery in heart valve centers of excellence.

Identifiants

pubmed: 36890195
doi: 10.1038/s41598-023-31163-0
pii: 10.1038/s41598-023-31163-0
pmc: PMC9995476
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3892

Informations de copyright

© 2023. The Author(s).

Références

JACC Cardiovasc Imaging. 2015 Jan;8(1):83-99
pubmed: 25592699
Circulation. 2001 Sep 18;104(12 Suppl 1):I59-63
pubmed: 11568031
JACC Cardiovasc Imaging. 2010 Mar;3(3):235-43
pubmed: 20223419
J Am Soc Echocardiogr. 2017 Dec;30(12):1162-1168
pubmed: 28807477
J Am Coll Cardiol. 2010 Aug 10;56(7):570-8
pubmed: 20688212
J Am Coll Cardiol. 2019 Jan 29;73(3):264-274
pubmed: 30678755
Ann Oncol. 2016 Jul;27(7):1185-9
pubmed: 27052655
J Am Coll Cardiol. 2019 Aug 20;74(7):858-870
pubmed: 31416529
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Heart. 2001 Mar;85(3):272-7
pubmed: 11179264
Am J Cardiol. 2006 May 15;97(10):1498-501
pubmed: 16679092
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442
Heart. 2010 Aug;96(16):1311-7
pubmed: 20659951
J Am Coll Cardiol. 2015 Mar 24;65(11):1078-88
pubmed: 25790878
JACC Cardiovasc Imaging. 2018 Sep;11(9):1213-1221
pubmed: 30031699
Eur Heart J. 2011 Mar;32(6):751-9
pubmed: 20829213
Circulation. 2021 Feb 2;143(5):e72-e227
pubmed: 33332150
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165
J Am Coll Cardiol. 2002 Jul 3;40(1):84-92
pubmed: 12103260
N Engl J Med. 2005 Mar 3;352(9):875-83
pubmed: 15745978
Am J Cardiol. 2015 May 15;115(10):1448-53
pubmed: 25784520
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116

Auteurs

Robert Zilberszac (R)

Department of Cardiology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. robert.zilberszac@meduniwien.ac.at.

Andreas Gleiss (A)

Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

Massimo Massetti (M)

Institute of Cardiology, Catholic University of Sacred Heart, Rome, Italy.

Wilfried Wisser (W)

Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.

Thomas Binder (T)

Department of Cardiology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Harald Gabriel (H)

Department of Cardiology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Raphael Rosenhek (R)

Department of Cardiology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. raphael.rosenhek@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH